CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 10:00:01 31/05/2024 pm IST | ||
| 4.28 EUR | +2.64% |
|
| 1 month | +9.74% | ||
| 3 months | +42.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 4.28 | +2.64% |
| 30/24/30 | 4.17 | +2.71% |
| 29/24/29 | 4.06 | -2.64% |
| 28/24/28 | 4.17 | -1.77% |
| 27/24/27 | 4.245 | -6.81% |
Real-time Euronext Paris
Last update May 31, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 4FLMB | |
| ISIN | NLBNPNL2IDW1 |
| Date issued | 20/09/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.15 € |
|---|---|
| Lowest since issue | 1.045 € |
| Spread | 0.2 € |
| Spread % | 4.57% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- 4FLMB Certificat
